Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:

Slides:

Advertisements

Similar presentations

Flow chart showing number of citations retrieved by individual searches and number of trials included in review Strippoli GF, et al. BMJ 2008 Feb 25 [Epub.

Advertisements

Protecting the heart and the kidney: Implications from the SHARP trial Dr. Christina Reith University of Oxford United Kingdom.

Weng TC, et al. J Clin Pharm Ther 2010;35:

* Plus–minus values are means ±SD. † Race was determined by the investigator. ‡ The body-mass index is the weight in kilograms divided by the square of.

Fenofibrate Intervention and Event Lowering in Diabetes FIELDFIELD Presented at The American Heart Association Scientific Sessions, November 2005 Presented.

ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)

Trial profile Prakash Deedwania, et al. Lancet 2006; 368:

6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.

Summary of “A randomized trial of standard versus intensive blood-pressure control” The SPRINT Research Group, NEJM, DOI: /NEJMoa Downloaded.

Dyslipidemia after Kidney Transplant

The SPRINT Research Group

Michael J. Koren, MD, Michael H. Davidson, MD, Daniel J

LDL cholesterol in CKD—to treat or not to treat?

Diabetic Cardiovascular Disease Predicts Chronic Kidney Disease Awareness in the Kidney Early Evaluation Program Cardiorenal Med 2011;1:45–52 - DOI: /

REVEAL: Randomized placebo-controlled trial of anacetrapib in 30,449 patients with atherosclerotic vascular disease Louise Bowman on behalf of the HPS.

Copyright © 2012 American Medical Association. All rights reserved.

AIM-HIGH Niacin Plus Statin to Prevent Vascular Events

Clinical Trials in Residual Cardiovascular Risk: A Fresh Perspective

Figure 6 Differences in glycaemic control with the study drug

Chapter 2: Pharmacological cholesterol-lowering treatment in adults

Switch to DTG-containing regimen

TNT Study: Baseline Characteristics of the Patients

Impact of Cognitive Function Change on Mortality in Renal Transplant and End-Stage Renal Disease Patients Sharma et al. Am J Nephrol 2016;44: (DOI: / )

Chronic Kidney Disease Classification in Systolic Blood Pressure Intervention Trial: Comparison Using Modification of Diet in Renal Disease and CKD-Epidemiology.

Figure 5 Risk factor control in the intensive treatment group

Fellström BC, et al. N Engl J Med 2009;360:1455-7

Selmer R, et al. Br J Clin Pharmacol 2009;67:355-62

Risk of perioperative renal dysfunction with N-acetylcysteine or placebo in patients undergoing CABG surgery End point N-acetylcysteine Placebo Relative.

Psychosocial Factors and 30-Day Hospital Readmission among Individuals Receiving Maintenance Dialysis: A Prospective Study Flythe et al. Am J Nephrol 2017;45:

Description of studies for pooled analyses

I. Introduction American Journal of Kidney Diseases

Screening, Lipid Stabilization, and Placebo Run-in

Pregnancy Outcomes in Patients with Glomerular Disease Attending a Single Academic Center in North Carolina O'Shaughnessy et al. Am J Nephrol 2017;45:

CKD cohort Non-CKD cohort Test Entire cohort, n=24 778

Subject Characteristics

Hajer GR et al. Atherosclerosis 2009;202:216-24

Forest plot of risk ratio with its 95% CI for the incidence of contrast-induced nephropathy among patient taking statin versus control based on renal impairment.

Screening, enrollment, and randomization of study participants (BMI, body mass index; CTG, conventional therapy group; HbA1c, glycated hemoglobin; HDL-C,

Potential mechanisms whereby statins may reduce the risk of stroke

Comparison of clinical and functional parameters among non-responders (=1) and responders (≥4) among healthy elderly and elderly patients with T2DM. Comparison.

Baseline Characteristics, Values at 24-Month Follow-up, and Changes from Baseline* - Part I John J.P. Kastelein, et al. N Engl J Med 2007;356: online.

Intensity of statin treatment and possible lipid lowering treatment intolerance and/or ineffectiveness issues among patients with type 2 diabetes (aged.

LDL cholesterol in CKD—to treat or not to treat?

Flow of Patients Through Trial

Study Participant Flow

Baseline Patients with coronary artery disease (CAD) and high (n=98) versus normal (n=1512) high-density lipoprotein (HDL) levels Doreen DeFaria Yeh, et.

Comparison of clinical and functional parameters between the CMV+ and CMV− participants in the healthy elderly and elderly patients with T2DM. Comparison.

Baseline Characteristics of the Subjects*

Baseline characteristics for patients with diabetes in ASCOT-LLA Part I P.S. SEVER et al Diabetes Care 2005; 28: 1151–1157.

Elevated High-Density Lipoprotein Cholesterol Is Associated with Hyponatremia in Hypertensive Patients Ariel Israel, MD, PhD, Ehud Grossman, MD The.

Nowak et al. Am J Nephrol 2016;44: (DOI: / )

Switch to DTG-containing regimen

Participation in Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Hisao Ogawa et al. JAMA 2008;300:

(A) Low-density lipoprotein-cholesterol (LDL-C) values at baseline and after treatment with anagliptin in 20 participants at 12 and 24 weeks. (A) Low-density.

Change in (A) total cholesterol; (B) LDL-cholesterol; (C) HDL-cholesterol and (D) triglycerides over 5 years in response to 12-week intensive lifestyle.

Baseline Characteristics of Elderly Participants in the Cardiovascular Health Study,According to Quintiles of Cystatin C Michael G.Shlipak et al N Engl.

Targeting Immunity in End-Stage Renal Disease

Characteristics of included studies

The ACCORD Study Group. NEJM 2010; Epub March 14

Universal Sustained Viral Response to the Combination of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with/without Ribavirin in Patients on Hemodialysis.

Recurrent Vascular Access Dysfunction as a Novel Marker of Cardiovascular Outcome and Mortality in Hemodialysis Patients Kim et al. Am J Nephrol 2016;44:71-80.

Change in markers of glycometabolism and cardiovascular risk profile.

Amir A. Mahabadi et al. JIMG 2017;10:

Volume 87, Issue 3, Pages (March 2015)

Correlation between progranulin (dependent variable) and CKD stage adjusted for age and sex, as well as DBP, WHR, triglycerides, HDL cholesterol, LDL cholesterol,

Flow of study participants

Individual lipid measures for high-carbohydrate (n=10) and low-carbohydrate (n=10) ultra-endurance athletes. Individual lipid measures for high-carbohydrate.

Fistula and Survival Outcomes after Fistula Creation among Predialysis Chronic Kidney Disease Stage 5 Patients Miyamoto et al. Am J Nephrol 2017;45:

Avasare et al. Am J Nephrol 2017;45:99-106 (DOI: / )

The cumulative incidence curve demonstrated that patients with a sub-optimal LDL-C response to statin therapy were associated with a higher risk of CVD.

Presentation transcript:

Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment: The Action to Control Cardiovascular Risk in Diabetes Study Papademetriou et al. Am J Nephrol 2017;45:136-145 (DOI:10.1159/000453626) Table 1. Baseline characteristics of study participants according to baseline CKD status

Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment: The Action to Control Cardiovascular Risk in Diabetes Study Papademetriou et al. Am J Nephrol 2017;45:136-145 (DOI:10.1159/000453626) Table 1 (continued). Baseline characteristics of study participants according to baseline CKD status

Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment: The Action to Control Cardiovascular Risk in Diabetes Study Papademetriou et al. Am J Nephrol 2017;45:136-145 (DOI:10.1159/000453626) Table 2. Baseline characteristics of study participants by baseline CKD status and treatment arm

Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment: The Action to Control Cardiovascular Risk in Diabetes Study Papademetriou et al. Am J Nephrol 2017;45:136-145 (DOI:10.1159/000453626) Table 2 (continued). Baseline characteristics of study participants by baseline CKD status and treatment arm

Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment: The Action to Control Cardiovascular Risk in Diabetes Study Papademetriou et al. Am J Nephrol 2017;45:136-145 (DOI:10.1159/000453626) Fig. 1. Lipid values with standard and intensive lipid therapy in CKD and non-CKD study participants. a Total cholesterol levels over time by baseline CKD status and lipid arm. b Triglyceride levels over time by baseline CKD status and lipid arm. c LDL-C levels over time by baseline CKD status and lipid arm. d HDL-C levels over time by baseline CKD status and lipid arm.

Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment: The Action to Control Cardiovascular Risk in Diabetes Study Papademetriou et al. Am J Nephrol 2017;45:136-145 (DOI:10.1159/000453626) Fig. 2. Rates of primary and secondary outcomes according to CKD status at baseline among participants in the lipid arm of the ACCORD study.

Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment: The Action to Control Cardiovascular Risk in Diabetes Study Papademetriou et al. Am J Nephrol 2017;45:136-145 (DOI:10.1159/000453626) Fig. 3. Rates for the primary and secondary outcomes by treatment group (intensive vs. standard) in patients with CKD (a) and without CKD (b) at baseline.

Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment: The Action to Control Cardiovascular Risk in Diabetes Study Papademetriou et al. Am J Nephrol 2017;45:136-145 (DOI:10.1159/000453626) Table 3. Adverse events by treatment group and CKD status